Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 17-26

  Chang, John Wen Cheng ^a   Hsieh, Jia Juan ^b   Shen, Yung Chi ^b   Yeh, Kun Yun ^c   Wang, Cheng Hsu ^c   Li, Ying Ying ^c   Hsu, Todd ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Gefitinib; Non small cell lung carcinoma; Zoledronic acid

Indexed keywords

CHELATING AGENT; DIVALENT CATION; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GERANYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENE MUTATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL SURVIVAL; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; PHOSPHONIC ACIDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

MUS; MUS MUSCULUS;

EID: 63449098528     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.019     Document Type: Article

References (39)

1. Robinson L.A. Top ten list in lung cancer. Chest 118 (2000) 228-229
2. Friedel G., Steger V., Kyriss T., Zoller J., and Toomes H. Prognosis in N2 NSCLC. Lung Cancer 45 (2004) S45-S53
3. Katakami N. Lung cancer with bone metastasis. Gan To Kagaku Ryoho 33 (2006) 1049-1053
4. Kawai H., Minamiya Y., Ito M., Saito H., and Ogawa J. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer 59 (2008) 41-47
5. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
6. Ozawa S., Ueda M., Ando N., Abe O., and Shimizu N. High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int. J. Cancer 39 (1987) 333-337
7. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural methothelioma. Cancer Res. 62 (2002) 5242-5247
8. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 3235-3242
9. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi H., Angeletti C.A., et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur. J. Cancer 31 (1995) 178-183
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-215
11. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3 (2004) 465-472
12. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21 (2003) 2237-2246
13. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
14. Yang C.-H. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 60 (2008) S23-S30
15. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350 (2004) 2129-2139
16. Huang S.-F., Liu H.-P., Li L.-H., Ku Y.-C., Fu Y.-N., Tsai H.-Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10 (2004) 8195-8203
17. Chang J.W.-C., Chou C.-L., Huang S.-F., Wang H.-M., Hsieh J.-J., Hsu T., and Cheung Y.-C. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 58 (2007) 414-417
18. Stresing V., Daubiné F., Benzaid I., Mönkkönen H., and Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett. 257 (2007) 16-35
19. Clézardin P., Ebetino F.H., and Fournier P.G.J. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 65 (2005) 4971-4974
20. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., and Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer 13 (2006) 7-26
21. Clézardin P., Fournier P., Boissier S., and Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. 10 (2003) 173-180
22. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006) 6222s-6230s
23. Fujita H., Utsumi T., Muranaka S., Ogino T., Yano H., Akiyama J., et al. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem. Pharmacol. 69 (2005) 1773-1784
24. Bezzi M., Hasmim M., Bieler G., Dormond O., and Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor -induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem. 278 (2003) 43603-43614
25. Wang C.H., Shen Y.C., Hsieh J.J., Yeh K.Y., and Chang J.W.C. Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J. Endocrinol. 190 (2006) 415-423
26. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid, alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
27. Li Y.-Y., Chang J.W.-C., Chou W.-C., Liaw C.-C., Wang H.-M., Huang J.-S., Wang C.-H., and Yeh K.-Y. Zoledronic acid is unable to induce apoptosis but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59 (2008) 180-191
28. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
29. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. D.W., Morse D., et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
30. Berenson J.R., Vescio R.A., Rosen L.S., Vonteichert J.M., Woo M., Swift R., et al. A phase I drug-ranging trial of monthly infusions of zoledronic acid for treatment of osteolytic bone metastases. Clin. Cancer Res. 7 (2001) 478-485
31. Ibrahim A., Scher N., Williams G., Sridhara R., Li N., Chen G., et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res. 9 (2003) 2394-2399
32. 1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 40 (2004) 43-51
33. Hara F., Aoe M., Doihara H., Taira N., Shien T., Takahashi H., et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett. 226 (2005) 37-47
34. Senaratne S.G., Mansi J.L., and Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane localization and induces cytochrome c release in breast cancer cells. Br. J. Cancer 87 (2002) 1340
35. Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., and Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease. Mol. Pharmacol. 71 (2007) 333-343
36. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsäläinen J., and Mönkkönen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147 (2006) 437-445
37. Hirata A., Ogawa O., Kometani T., Kuwano T., Naito S., and Kuwano M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62 (2002) 2554-2560
38. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., and Clézardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
39. Hashimoto K., Morishige K., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354 (2007) 478-484